Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;7(17):404.
doi: 10.21037/atm.2019.07.52.

The dilemma of aspirin resistance in obese patients

Devarshi Ardeshna  1 , Sarthak Khare  2 , Pooja S Jagadish  3 , Venugopal Bhattad  4 , Brandon Cave  5 , Rami N Khouzam  6
Affiliations
Review

The dilemma of aspirin resistance in obese patients

Devarshi Ardeshna et al. Ann Transl Med. 2019 Sep.

Abstract

Aspirin resistance (AR) commonly refers to the concept of reduced aspirin efficacy in preventing cardiovascular disease and platelet inhibition. Obesity increases the risk of heart disease three- to four-fold and has been associated with AR. Aspirin is used as a tool for both primary and secondary prevention, but recent studies suggest that its lack of efficacy for primary prevention is partly attributable to obesity. Several mechanisms have been described that contribute to AR in obese patients using pharmacokinetics and pharmacodynamics. AR may be attenuated through weight loss, alternative dosing regimens, and different drug formulations. With the global rise of obesity, it is imperative to find preventive therapies that adequately address atherosclerotic cardiovascular disease (ASCVD) risk in this population.

Keywords: Aspirin resistance (AR); aspirin; obesity.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Dr. Cave discloses that he serves on the speaker’s bureau for Portola pharmaceuticals. The other authors have no conflicts of interest to declare.

References

    1. Arnett DK, Blumenthal RS, Albert MA, et al. 2019. ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019 [Epub ahead of print]. - PMC - PubMed
    1. Hennekens CH, Dyken ML, Fuster V. Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1997;96:2751-3. 10.1161/01.CIR.96.8.2751 - DOI - PubMed
    1. ASCEND Study Collaborative Group , Bowman L, Mafham M, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med 2018;379:1529-39. 10.1056/NEJMoa1804988 - DOI - PubMed
    1. Gaziano JM, Brotons C, Coppolecchia R, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet 2018;392:1036-46. 10.1016/S0140-6736(18)31924-X - DOI - PMC - PubMed
    1. McNeil JJ, Nelson MR, Woods RL, et al. Effect of Aspirin on All-Cause Mortality in the Healthy Elderly. N Engl J Med 2018;379:1519-28. 10.1056/NEJMoa1803955 - DOI - PMC - PubMed

LinkOut - more resources